B2B ad examples

Discover clinical development strategies for advancing CAR-T into autoimmune and chronic disease indications. Download the whitepaper.

Download the whitepaper and explore how patient needs, risk tolerance and long-term follow-up reshape immunotherapy trials beyond oncology.

Imaging is more than image collection. It’s the workflow connecting sites, image quality, readers, central review and clinical endpoints. Collective Minds brings that journey together in one centralized platform, giving sponsors greater visibility across the imaging workflow. Connect your imaging workflow. Keep your trials moving toward endpoints.

Clinical trial imaging doesn’t happen in isolation. It connects sites, quality control, readers, central review and ultimately the clinical endpoints that matter. Collective Minds brings these workflows together in one centralized platform, helping sponsors gain visibility and reduce fragmentation across their studies. One connected imaging workflow. A clearer path to your endpoints.

You don’t have to choose between process efficiency and a cleaner label. Nutracore® LFP is an organic lubricant that delivers superior flow for capsule and tablet formulations, helping you reduce processing issues and keep production moving. Discover how easily Nutracore LFP integrates into your process to support reliable, high‑quality output.

Pharmacien hospitalier : le métier de l'ombre ? 👁️ Hier, c'était la Journée Mondiale des Pharmaciens. L'occasion de lever le voile sur cette spécialité encore méconnue. Les pharmaciens hospitaliers ne représentent qu'un pharmacien sur dix en France. Un métier essentiel, mais qui reste largement dans l'ombre. Amine Benhabib , pharmacien hospitalier à Clinique de l'Estrée - GROUPE ELSAN, en dévoile les coulisses : garantir la sécurité de milliers de références de dispositifs médicaux, superviser la stérilisation du matériel chirurgical, veiller à ce que chaque médicament arrive au bon patient, au bon moment... Sa comparaison est parlante : "Une opération de chirurgie, c'est un peu comme un vol en avion." Le chirurgien opère. En coulisses, l'équipe pharmacie participe à la préparation, à la vérification et à la sécurisation des dispositifs. Merci à Amine pour ce témoignage et à tous les pharmaciens hospitaliers qui œuvrent au quotidien dans nos établissements et ailleurs, pour la santé de tous. 💚 #Pharmacien #Santé

Does every stage of RNA development need the same level of analytical resolution? Probably not. In our latest discussion on RNA manufacturing, Ashish Dhir, Mark Dickman and Francis Combes explore why a tiered approach to analytics could help teams balance speed, cost and analytical depth. For 5′ cap analysis, rapid or semi-quantitative methods can support process development, while higher-resolution approaches such as LC-MS can provide deeper characterisation later in development. The same trade-offs appear in residual DNA control. qPCR and ddPCR offer powerful detection capabilities, while DNase treatment introduces its own process considerations, from enzyme removal to performance under IVT conditions. The recurring question throughout the conversation: How can we generate analytical data quickly enough to improve the manufacturing process, without compromising the depth of information needed later? 🎧 Explore the full discussion: https://lnkd.in/eqNkdbyY

300 ans après sa mort, Louis XIV pourrait-il nous révéler une maladie rénale ? 🔎 C’est en se plongeant dans les récits historiques sur les derniers jours du Roi Soleil que le Dr Stanislas Bataille, néphrologue à la Clinique Bouchard (HÔPITAUX PRIVES DE CÔTE D'AZUR ET DE PROVENCE - ELSAN) à Marseille, s’est interrogé sur les causes réelles de sa mort. À l’époque, le diagnostic posé est celui d’une gangrène. Mais certains symptômes décrits par les contemporains de Louis XIV interpellent le médecin : pourraient-ils correspondre à une complication sévère de l’insuffisance rénale chronique ? Pour confronter cette hypothèse aux données scientifiques, le Dr Bataille s’est associé au paléopathologue Philippe Charlier. Leur travail croise ainsi deux expertises : la médecine d’aujourd’hui et l’étude des traces laissées par le passé. Une démarche qui illustre aussi le rôle essentiel des médecins dans la recherche : observer, questionner les certitudes, formuler des hypothèses et chercher les preuves pour faire progresser les connaissances. Au-delà de l’histoire de Louis XIV, cette recherche contribue à mettre en lumière une maladie qui reste aujourd’hui encore trop peu connue : l’insuffisance rénale chronique. 👉 Plus d'infos sur l'étude : https://lnkd.in/exvyf-SA INSTITUT PHOCEEN DE NEPHROLOGIE, Eva GARNIER, Myriam Combes, Nathalie PEDINIELLI #Recherche #Néphrologie #Santé

What can visual inspection reveal about manufacturing quality? Consistent inspection starts with an understanding of the product, its container, and the defects that may arise during manufacturing. In our latest article, we explore the AMClarity approach: risk assessment, tailored defect kits, microscopic characterization, and operator qualification. The article includes photographs of defect preparation and measurement, and considers how inspection data can guide process improvement. Read the article for a closer look at the process. #Anemocyte #AMCForward #BiotechInnovation

🎙️ RNA quality is measurable. But how well does it predict biological function? In Episode 1 of RNA on Air, our panel asks a fundamental question: Are we measuring the right things? The discussion explores why it’s still challenging to connect RNA quality attributes with biological performance, and where today’s QC workflows may be falling short. From assay standardization and analytical sensitivity to structural characterization, there’s plenty to unpack. Join Francis Combes, Mark Dickman and Ashish Dhir for the conversation. 🎧 Listen to Episode 1: From RNA quality to biological function: https://lnkd.in/eqNkdbyY What needs to change to better connect RNA quality with function?

Elevate your pathology lab with Aiforia® Breast Cancer Suite – enhancing precision, speed, and diagnostic accuracy with cutting-edge AI technology. Aiforia® Breast Cancer Suite consists of AI models with an optimized interactive user interface that supports pathologists in the histological grading of breast cancer and in the assessment of breast cancer IHC markers. Request a demo to see a more detailed overview of the features. ⬇️

Breast Cancer Awareness Month is a powerful reminder of the vital role pathology plays in patient outcomes. But growing workloads demand faster, more consistent diagnostic insights. Aiforia’s Breast Cancer Suite–a comprehensive portfolio of CE-IVD marked AI models–empowers pathologists to deliver faster, more consistent, data-driven insights, improving diagnostic accuracy and patient outcomes. Learn more: https://lnkd.in/dApWDa3k/?utm_campaign=BCSuite%25E2%2580%2593Leadform%25E2%2580%2593Q42026&utm_source=linkedin&utm_medium=paid&utm_id=1229053903&hsa_acc=502575710&hsa_cam=1229053903&hsa_grp=896190383&hsa_ad=1592710023&hsa_net=linkedin&hsa_ver=3

ESMO begins in just a few days, and I’m looking forward to connecting with peers and seeing the latest advances in cancer care from across the R&D and medical community. Ahead of this year’s congress, David Fredrickson and I reflected on 10 years of progress in oncology. We discussed what has had the most impact on cancer care in the past decade and our predictions for the future. Watch until the end to hear our personal lessons learnt over this time! What do you think has been the biggest breakthrough in cancer care in the past decade? #ESMO26

Cancer care has come a long way in 10 years. What could the next decade bring? Ahead of ESMO, we asked David Fredrickson and Susan Galbraith to look back on the advances that have transformed cancer treatment – and look ahead to the breakthroughs that could shape the future. Watch their conversation. #ESMO26

🧬Introducing lunresertib In July 2025, Debiopharm acquired the exclusive worldwide rights to lunresertib from @Repare Therapeutics. Lunresertib is a first-in-class, selective and potent, oral small-molecule inhibitor of PKMYT1, a cancer target identified as synthetically lethal in solid tumors with CCNE1 amplification and alterations in FBXW7 and PPP2R1A. Together with zedoresertib, lunresertib adds an additional row to Debiopharm’s DDR domino cascade. As a leading selective PKMYT1 inhibitor in clinical development, lunresertib has demonstrated encouraging activity across multiple clinical trials in difficult-to-treat solid tumors. Positive initial Phase 1 data from the ongoing MYTHIC trial (NCT04855656) provide proof of concept for lunresertib as monotherapy and in combination. 👇 Find out more about lunresertib https://lnkd.in/dUeS9ztr #DNADamageResponse #DDR #PKMYT1 #Oncology #Debiopharm

Distributing IVD products? Meet Calpro at MEDICA to discuss calprotectin testing in your market. Does your company distribute in vitro diagnostics? Calpro is meeting distribution companies at MEDICA in Düsseldorf, 16–19 November, to discuss calprotectin testing in new markets. Book a meeting in advance: https://lnkd.in/eyPDdxFe

𝗢𝗽 𝘄𝗲𝗴 𝗻𝗮𝗮𝗿 𝗠𝗗𝗥: 𝗩𝗲𝗶𝗹𝗶𝗴𝗲 𝗔𝗜 𝗶𝗻 𝗱𝗲 𝘇𝗼𝗿𝗴, 𝘄𝗮𝘁 𝗸𝗼𝗺𝘁 𝗱𝗮𝗮𝗿 𝗮𝗹𝗹𝗲𝗺𝗮𝗮𝗹 𝗯𝗶𝗷 𝗸𝗶𝗷𝗸𝗲𝗻? De adoptie van nieuwe technologie begint bij het vertrouwen hierin. Wanneer een zorgprofessional een gesprek samenvat met de Attendi App, zijn er terechte vragen. Haalt de AI de juiste informatie eruit? Verzint die geen dingen? “De AI werkt goed” is daarbij niet een antwoord dat volstaat. Binnen het MDR-certificeringstraject richten we ons kwaliteitsmanagementsysteem (QMS) in volgens ISO 13485, de internationale norm voor medische hulpmiddelen waaronder medische software. Onderdeel van dit QMS is het technisch dossier. Hierin komen de beoogde toepassing van het product, risicoanalyses, ontwerpkeuzes, testresultaten en klinische onderbouwing samen. Samen moeten deze een controleerbare bewijsketen vormen, zodat het antwoord op deze vragen te verifiëren is en niet slechts wordt beweerd. In het bijbehorende artikel lichten we de punten uit de video verder toe: https://lnkd.in/em2wyuXr 𝘋𝘦 𝘈𝘵𝘵𝘦𝘯𝘥𝘪 𝘈𝘱𝘱 𝘪𝘴 𝘰𝘱 𝘥𝘪𝘵 𝘮𝘰𝘮𝘦𝘯𝘵 𝘨𝘦𝘦𝘯 𝘊𝘌-𝘨𝘦𝘮𝘢𝘳𝘬𝘦𝘦𝘳𝘥 𝘮𝘦𝘥𝘪𝘴𝘤𝘩 𝘩𝘶𝘭𝘱𝘮𝘪𝘥𝘥𝘦𝘭. 𝘋𝘦 𝘔𝘋𝘙 𝘒𝘭𝘢𝘴𝘴𝘦 𝘐𝘐𝘢 𝘤𝘰𝘯𝘧𝘰𝘳𝘮𝘪𝘵𝘦𝘪𝘵𝘴𝘣𝘦𝘰𝘰𝘳𝘥𝘦𝘭𝘪𝘯𝘨 𝘷𝘰𝘰𝘳 𝘩𝘦𝘵 𝘴𝘢𝘮𝘦𝘯𝘷𝘢𝘵𝘵𝘦𝘯 𝘭𝘰𝘰𝘱𝘵 𝘯𝘰𝘨. 𝘝𝘰𝘭𝘨 𝘰𝘯𝘴 𝘰𝘮 𝘰𝘱 𝘥𝘦 𝘩𝘰𝘰𝘨𝘵𝘦 𝘵𝘦 𝘣𝘭𝘪𝘫𝘷𝘦𝘯 𝘷𝘢𝘯 𝘩𝘦𝘵 𝘷𝘦𝘳𝘥𝘦𝘳𝘦 𝘷𝘦𝘳𝘭𝘰𝘰𝘱 𝘷𝘢𝘯 𝘩𝘦𝘵 𝘵𝘳𝘢𝘫𝘦𝘤𝘵.

🧬The MYTHIC trial This Phase 1/1b, multi-center, open-label, dose-escalation study is currently being executed in biomarker-selected patients (CCNE1 amplification or deleterious FBXW7/PPP2R1A alterations), reflecting a shared biology of heightened replication stress and checkpoint dependency. (NCT04855656) Module 4 of the study is designed to evaluate safety and tolerability, define MTD and RP2D, characterize PK and pharmacodynamics, and assess preliminary anti-tumor activity for lunresertib in combination with zedoresertib. As presented at AACR 2026, early data readouts from MYTHIC suggest synthetic lethality between lunresertib and zedoresertib, with consistent tumor regressions observed. Strong signals of activity were observed with the combination, particularly in patients with platinum resistant or refractory ovarian cancer. 👇 Read more about lunresertib and the MYTHIC trial https://lnkd.in/dUeS9ztr https://lnkd.in/dfAtKP2M #DNADamageResponse #DDR #PKMYT1 #WEE1 #Oncology #ClinicalTrial #Debiopharm

What if every reimbursement decision could benefit from the experience of thousands of healthcare providers? Meet Aptarro Prism. Powered by intelligence from 500M+ annual transactions and reimbursement patterns across a network serving 130K+ providers, Prism helps your team identify opportunities, anticipate denials, and act at the point-of-decision.

Which markets need calprotectin testing? You know yours. Tell us about it at MEDICA. Your company knows its market: the laboratories, the clinicians and the tenders. We are meeting distributors at MEDICA in Düsseldorf, 16–19 November, to discuss calprotectin testing in new markets. https://lnkd.in/eyPDdxFe

The cost of not treating #dryeye may be greater than you think. Dry eye disease can affect more than the eyes, potentially impacting patients’ emotional wellbeing and everyday activities. Join eye care experts Drs. Laura M Periman, MD and Jackie Garlich, O.D., F.A.A.O for a LinkedIn Live discussion as they explore the often-overlooked impact of delayed care and why earlier recognition and appropriate intervention matter. 📅 November 17 ⏱️ 2:00 PM EST 📍 Bausch + Lomb LinkedIn Click “Register” to save your spot and receive event reminders: https://lnkd.in/gz_Drixm #SeeBetterLiveBetter #EyeHealth #Optometry #Ophthalmology #DED

Benchmark performance, uncover opportunities for improvement, and prioritize the decisions that matter most. Prism brings together reimbursement patterns, payer signals, and insights from across the Aptarro network to help your team see more, before it costs you a reimbursement.

When kidney filters are damaged, a protein called albumin leaks into the urine. This leakage signals widespread inflammation that can damage the heart and brain, increasing the risk of heart attack and stroke. Through Detect the SOS, we're working with partners to make sure this signal doesn't go unnoticed. A simple urine test can help detect this warning sign early. The urine albumin-to-creatinine ratio (uACR) test is a quick, simple way to identify this risk, especially for people living with type 2 diabetes or high blood pressure. 🎥 Watch Dr Neerja Balachander, Vice President for US Clinical Development Medical Affairs, Cardiovascular-Renal-Metabolism at Boehringer Ingelheim, discuss the importance of uACR testing at the Foreign Policy Health Forum. #DetectTheSOS #uACR #HeartHealth #KidneyHealth #GlobalHealth #UNGA81

We hear a version of the same question in almost every customer conversation and RFP: can we use generative AI in research workflows, and if so, how do we make sure the outputs pass regulatory scrutiny? The concern is legitimate. A peer-reviewed study published in JMIR Publications Mental Health in November 2025 found that nearly 20% of citations generated by GPT-4o in simulated literature reviews were fabricated, rising to 29% in less familiar or specialized topics. ISPOR—The Professional Society for Health Economics and Outcomes Research 's ELEVATE-GenAI framework, published in Value in Health in November 2025, sets out what HEOR teams need to document when LLMs play a substantive role in their evidence. It is already referenced in NiCE 's position statement on AI in HTA submissions, and CDA and G-BA are following suit. Organizations submitting HEOR evidence to these bodies will increasingly be expected to document AI use against its 10 domains. Every extraction must be traceable to its source document. Model version and update governance must be documented. Outputs must be reproducible from the same document, prompt, and model version. Confidence levels must be communicated. All AI activity must be logged. General-purpose LLMs used through a chat interface cannot meet these requirements. Their outputs are non-deterministic by design, and training data provenance is opaque. The variability and inference beyond the source that make them useful for open-ended tasks are the same properties that make them indefensible in a regulatory submission. This is a problem specific to general-purpose LLMs. Deterministic AI has been part of systematic review workflows for years, including our own. DistillerSR's Smart Evidence Extraction (SEE) was purpose-built for regulated evidence environments. Every extraction is source-cited, every model version is traceable, and every AI suggestion requires a human decision that is logged to the audit record. Customer data is never used to train third-party models. Our new white paper maps SEE against all 10 ELEVATE-GenAI domains and explains what that means in practice for teams preparing HTA submissions. Read the white paper: https://lnkd.in/gsWtnn8M